Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy

Subcutaneous immunoglobulin (SCIG) therapy is increasingly used to treat chronic inflammatory demyelinating polyneuropathy (CIDP). To support patient-centered care and improve adherence, we evaluated which SCIG treatment attributes matter most to patients and compared experiences using pre-filled syringes (PFS) versus vials.

A conjoint analysis was conducted with n = 187 Ig-using patients with CIDP from the USA and Canada to quantify the relative importance of attributes related to self-administered subcutaneous therapy. Following this, a survey of n = 68 SCIG users assessed real-world experiences and preferences with PFS and vial-based administration, including outcomes among patients with CIDP who switched to PFS.

The main drivers of preference in subcutaneous therapies were ease of preparation (31% of relative importance) and likelihood of getting sick after infusion (27% of relative importance). Injection volume and skin reaction ranked third (23% of relative importance). In the survey, PFS users reported that administering their infusions was more convenient (7-point scale, median 6 vs median 5, respectively) and they were more confident administering their infusions than vial users (completely or very confident, 98% vs 84%, respectively). More PFS users reported feeling "better than usual" within the first day post-infusion compared with vial users (51% vs 20%, respectively). Among patients who switched from vials to PFS (n = 17), 71% reported higher treatment satisfaction, 82% found PFS more convenient, and 65% reported faster administration with PFS.

PFS aligns with key preference drivers for self-administered SCIG therapy in CIDP compared to vials. These findings highlight the value of integrating patient-prioritized treatment attributes and preferences into clinical decision-making.